Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D. C. 20549
____________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act Of 1934
Date
of
Report (Date of earliest event reported)
___________________________________________________________
ACURA
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in Charter)
___________________________________________________________
|
State
of New York
|
1-10113
|
11-0853640
|
|
(State
of Other Jurisdiction
|
(Commission
File Number)
|
(I.R.S.
Employer
|
|
of
Incorporation)
|
|
Identification
Number)
|
616
N. North Court, Suite 120
Palatine,
Illinois 60067
(Address
of principal executive offices) (Zip Code)
(847)
705-7709
(Registrant’s
telephone number, including area code)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
Written
communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the
Exchange Act (17CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule
14d-2(b) under the Exchange Act (17CFR240.14d- 2(b))
o
Pre-commencement
communications pursuant to Rule
13e-4(c) under the Exchange Act (17CFR 240.13e- 4(c))
Item
2.02 Results
of Operations and Financial Condition
On
October
27, 2008,
the
Registrant issued a press release disclosing the financial results for its
third
quarter ended September 30, 2008. A copy of the Registrant’s press release is
furnished as Exhibit 99.1 hereto.
Item
9.01 Financial
Statements and Exhibits
Exhibit
Number
Description
99.1 Press
Release dated October
27, 2008
Announcing Financial Results for the Third Quarter of 2008
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
| |
|
|
| |
ACURA
PHARMACEUTICALS, INC. |
|
|
|
| |
By: |
/s/ Peter
A.
Clemens |
| |
Peter
A. Clemens |
| |
Senior
Vice President & Chief Financial
Officer |
Date: October
27, 2008
Exhibit
Index
Exhibit
Number
Description
99.1
Press
Release dated October
27, 2008
Announcing Financial Results for the Third Quarter of
2008